Oct 2026· Asian Pacific Journal of Cancer Prevention· Vol 27 10, pp.
3619-3627
· 0 citations· 28 references
Medicine
TL;DR
FAP+ regions, in contrast to FAP- clusters, exhibited dense fibrosis, distinct metabolic profiles, and altered immune signatures, supporting the use of combined FAP-targeted radionuclide therapy with radiosensitizers.
Abstract
INTRODUCTION
The spatial heterogeneity of the tumor microenvironment in gastric cancer, particularly in the stromal compartment, remains poorly characterized. Fibroblast activation protein (FAP)-positive cancer-associated fibroblasts (CAFs) are known to promote tumor progression, immune evasion, and therapeutic resistance. However, the spatial transcriptional programs of FAP+ and FAP- stroma and their associations with response to immunotherapy are not fully understood.
MATERIAL AND
Methods
Formalin-fixed, paraffin-embedded (FFPE) gastric cancer tissue sections were analyzed with the 10x Genomics Visium Spatial Gene Expression platform, and IHC was used to validate the transcriptional findings.
Results
The FAP+ stromal regions displayed a transcriptional profile characterized by extensive extracellular matrix remodeling (COL1A1, FN1, SPARC), immunosuppressive signaling (GREM1, C1S, IFI44), and high expression of canonical CAF markers (ACTA2, TAGLN). In contrast, FAP- regions retained epithelial features, indicating a closer proximity to tumor cells, and showed enrichment in antigen presentation and interferon signaling pathways. Pathway analysis confirmed the divergence in functional states between these stromal regions. Importantly, FAP+ regions in non-responders to immunotherapy exhibited overexpression of fibrosis- and stemness-associated genes, along with immunosuppressive chemokines (CCL20/28), whereas responders demonstrated robust interferon signaling, antigen processing, and epithelial differentiation. Expression of CD24 in fibroblasts was validated by immunohistochemistry, confirming transcriptomic data and suggesting potential new drug targets in tumor stroma.
Conclusion
FAP+ regions, in contrast to FAP- clusters, exhibited dense fibrosis, distinct metabolic profiles, and altered immune signatures. Non-responders to immunotherapy displayed a fibrotic, immunosuppressive FAP+ signature associated with stemness and radioresistance, supporting the use of combined FAP-targeted radionuclide therapy with radiosensitizers. Conversely, responders' FAP+ niches showed immune activation and interferon signaling, favoring immunomodulatory treatments.
Background The role of Filamin A (FLNA) in colorectal cancer (CRC), particularly within the stromal compartment, remains poorly defined. This study investigates its expression, function, and clinical relevance in CRC. Methods We integrated transcriptomic data from the GSE39582 training cohort and TCGA/GSE75316 validati...
Q. Yao, Ning-Bo Liu, Shi-Long Li et al.· Journal of Cancer· 0 citations
Oxidative stress response (OSR) is suggested as a therapeutic target in triple negative breast cancer (TNBC). However, the cell type specificity and spatial distribution of OSR genes and proteins remain poorly defined. We re-analyzed public datasets, demostrating high OSR gene expression in TNBC tumor cells. We gener...
CAF abundance is negatively correlated with immune infiltration at the spatial level, with ECM remodeling and FN1-ITGB1 signaling potentially mediating this immune exclusion in melanoma.
Lung adenocarcinoma (LUAD) is the leading subtype of non-small cell lung cancer. However, the stromal-immune circuits that coordinate matrix remodeling and immunotherapy resistance in LUAD remain incompletely understood. This study aimed to characterize the stromal-immune interactions associated with LUAD progression a...
Meng-Lei Wang, Peng-Cheng Zhang, Xue-Feng Li et al.· Journal of Translational Med...· 0 citations
These findings identify a candidate AKR1C3-associated epithelial–stromal–myeloid spatial configuration in gastric cancer, and proof-of-concept evidence of close spatial proximity among the corresponding marker-defined populations is provided.
Jing-Jing Yang, Yi-Xuan Dai, Jian-Peng Sheng et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.